OncoTherapy Science, Inc. (TYO:4564)
Japan flag Japan · Delayed Price · Currency is JPY
20.00
0.00 (0.00%)
Aug 6, 2026, 2:00 PM JST

OncoTherapy Science Balance Sheet

Millions JPY. Fiscal year is Apr - Mar.

Assets

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
2,0898335271,1171,836
Cash & Short-Term Investments
2,0898335271,1171,836
Cash Growth
150.78%58.06%-52.82%-39.16%-36.67%
Accounts Receivable
1039835123399
Other Receivables
--153--
Receivables
10398188123399
Inventory
62787399231
Other Current Assets
55962983134
Total Current Assets
2,3091,1058171,4222,600
Long-Term Investments
4949498984
Other Long-Term Assets
111-1
Total Assets
2,3591,1558671,5112,685

Liabilities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Current Income Taxes Payable
142163141318558
Other Current Liabilities
2716421829146
Total Current Liabilities
169327359609604
Other Long-Term Liabilities
4910015548102
Total Liabilities
218427514657706

Shareholders' Equity

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
505050789789
Additional Paid-In Capital
29,83927,51626,32224,79324,793
Retained Earnings
-27,818-26,908-26,092-24,804-23,686
Comprehensive Income & Other
7070737683
Total Common Equity
2,1417283538541,979
Shareholders' Equity
2,1417283538541,979
Total Liabilities & Equity
2,3591,1558671,5112,685

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash (Debt)
2,0898335271,1171,836
Net Cash Growth
150.78%58.06%-52.82%-39.16%-36.67%
Net Cash Per Share
6.363.192.485.809.79
Filing Date Shares Outstanding
398.64277.64239.34206.64192.64
Total Common Shares Outstanding
383.64271.64217.64192.64192.64
Working Capital
2,1407784588131,996
Book Value Per Share
5.582.681.624.4310.27
Tangible Book Value
2,1417283538541,979
Tangible Book Value Per Share
5.582.681.624.4310.27